Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

Novo Nordisk investing in rare disease with major new manufacturing site

1
SHARES

A total of DKK 8.5 billion will fund the new production facility in Odense, Denmark, which is set to facilitate the manufacture of medicines for rare diseases.

Novo Nordisk, Odense, Denmark production facility

Credit: Novo Nordisk. 3D render of planned new production facility and warehouse in Odense, Denmark.

Novo Nordisk is planning a new investment, which marks the first time this millennium that the pharmaceutical company breaks ground in Denmark by establishing a new production site.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

A total of DKK 8.5 billion will be used for the new facility in Odense, Denmark.

Once complete, the site will feature a “modular and flexible” finished production facility and warehouse spanning over 40,000m2. Novo Nordisk explained that its capacity will enable multiple product types for rare diseases, such as haemophilia, to be accommodated.

“The [Odense, Denmark] facility will utilise advanced technology and innovative equipment to ensure the highest quality to patients”

“The facility will utilise advanced technology and innovative equipment to ensure the highest quality to patients and meet the growing global demand,” commented Henrik Wulff, Executive Vice President, Product Supply, Quality & IT of Novo Nordisk.

Furthermore, the project will support preservation of the surrounding environment, the company stated. Over 4,000 new trees are planned to be planted at the site and reuse of “excess soil, wooden materials and other sustainable resources” will be utilised to create natural public spaces. Additionally, the building infrastructure will also feature solar panels, according to Novo Nordisk.

The investment will also provide economic benefit, with 400 permanent jobs anticipated to be generated following completion of the site. Construction is expected to be finished in 2027, the pharma company confirmed.

Novo Nordisk’s continued commitment to enhancing manufacturing capacity

In June, Novo Nordisk announced a multi-billion investment in the US. Similar to the firm’s new investment in Denmark, expansion of its North Carolina facility boasts environmentally sustainable credentials, eg, solar panels and advanced technologies.

Moreover, early in 2024, Novo Nordisk made another major multi-billion-dollar commitment through its agreed acquisition of three fill-finish manufacturing sites from Novo Holdings A/S (Novo Holdings) for a total of $11 billion.

Share via
Share via